|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.765 USD | -1.40% |
|
-5.29% | -80.18% |
| 07-16 | EnGene Therapeutics Initiates Planned BLA Submission For Detalimogene Voraplasmid And Provides Updates On LEGEND Phase 2 Trial | CI |
| 07-16 | Engene Therapeutics Inc. Announces Board Changes | CI |
Main competitors
| Change | 5-day change | 1-month change | 3-month change | YTD change | 1-year change | 3-year change | 5-year change | 10-year change | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
 | -1.40% | -5.29% | +3.47% | -75.38% | -80.18% | -48.86% | -83.41% | - | - | 118M | |
| +2.35% | +0.77% | +3.15% | +17.23% | +41.69% | +29.92% | +85.38% | -14.38% | - | 55.23B | |
| -0.21% | -7.38% | -6.12% | +8.85% | +3.93% | +25.34% | +63.02% | +185.44% | +5,966.78% | 53.75B | |
| -2.27% | +1.97% | -3.01% | -6.61% | -4.32% | -15.27% | -16.33% | -73.23% | - | 23.48B | |
| -3.55% | -8.32% | -8.39% | -26.44% | -43.68% | -8.63% | +343.73% | +306.22% | +743.55% | 22B | |
| +2.49% | -1.27% | +11.97% | +17.25% | +23.22% | +15.99% | -10.53% | -67.31% | - | 19.78B | |
| +0.79% | -1.06% | +3.25% | +9.71% | -8.31% | +29.29% | -33.32% | -34.77% | +52.59% | 17.44B | |
| +0.58% | -7.23% | +10.91% | +3.07% | +23.36% | +24.50% | +519.07% | - | - | 14.66B | |
| -4.88% | -3.43% | -0.91% | +22.41% | +21.99% | +47.63% | +171.28% | +210.33% | +476.81% | 14.07B | |
| +3.41% | -7.83% | -12.25% | +77.89% | +150.18% | +161.76% | +284.91% | +1,349.84% | +609.16% | 13.02B | |
| -6.53% | -15.08% | -10.11% | -9.99% | -20.59% | +52.86% | +125.24% | +425.94% | +6,611.32% | 11.37B | |
| -2.53% | -0.15% | +6.25% | +14.25% | +28.74% | +440.95% | +147.60% | +25.67% | +1,358.53% | 12.3B | |
| +0.80% | -8.61% | +6.70% | -30.82% | -16.86% | -38.51% | +118.74% | +82.25% | - | 10.95B | |
| -3.16% | -2.85% | -8.00% | +23.82% | +23.45% | +108.40% | +135.20% | +172.65% | +582.68% | 10.92B | |
| -1.64% | -2.86% | -7.72% | -17.65% | -24.13% | -49.68% | +531.90% | +71.23% | +99.55% | 10.72B | |
| +0.16% | +0.05% | +116.57% | +114.68% | +79.96% | +193.00% | +340.89% | +378.14% | - | 8.82B | |
| -3.39% | -3.50% | +10.88% | +41.98% | +200.85% | +480.79% | +597.65% | -35.90% | -17.35% | 8.93B | |
| +2.96% | -6.36% | +10.03% | -18.74% | +13.54% | +26.35% | +72.47% | -17.63% | - | 7.93B | |
| -3.77% | -10.73% | +1.83% | +20.09% | +6.77% | +13.22% | +297.28% | +312.16% | - | 7.69B | |
| -2.76% | -0.13% | -2.66% | -4.11% | +18.31% | +60.80% | +13.59% | +142.84% | - | 8.08B | |
| Average | -1.13% | -2.96% | +6.29% | +9.07% | +21.90% | +77.49% | +185.22% | +189.97% | +1,648.36% | 16.56B | |
| Weighted average by Cap. | -0.52% | -1.13% | +2.82% | +11.23% | +21.44% | +58.78% | +154.68% | +151.42% | +2,588.91% |
- Stock Market
- Stocks
- ENGN Stock
- Sector enGene Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
